ALISO VIEJO, Calif., April 28 /PRNewswire/ -- MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral vascular and peripheral diseases, announced today that it has named former Baush & Lomb Surgical Division executive Christopher M. Owens, Vice President Worldwide Marketing. He will report directly to MicroVention President and Chief Executive Officer R. Michael Kleine.
Owens brings 15 years of medical device sales, marketing and development experience to MicroVention, including an extensive background in new product development and creating and implementing strategic and tactical programs to gain global market product acceptance for new and established medical products.
"With his years of successful strategic marketing management and medical device sales experience, Chris is a great addition to our senior management team," Kleine said. "We have introduced and established a strong presence for both our MicroPlex and HydroCoil products in the U.S. and international markets and are now poised to accelerate sales of those innovative products and take additional worldwide market share going forward. We believe Chris will play an integral part in ensuring the success of that effort."
Owens comes to MicroVention from Rochester, NY-based Bausch & Lomb where his most recent position was Acting Vice President of Global Research and Development responsible for the implementation of all programs affiliated with that company's Surgical Division. Prior to that he was Vice President Worldwide Marketing, at Foothill Ranch, CA-based Cardiogenesis Corporation, where he was instrumental in launching the strategy and platform for market adoption and branding of the company and its product portfolio. Owens has also held managerial and senior staff positions at Imagyn Medical Technologies, Stackhouse Incorporated, a division of Thermo-Electron Corporation, and Edwards Lifesciences, formerly Baxter Healthcare Corporation.
Owens earned a BS and MS in Engineering from the University of Massachusetts at Lowell and an MBA from the University of Phoenix. Chris resides with his wife in Huntington Beach, CA.
MicroVention currently markets its MicroPlex Coil System and HydroCoil Embolic System (HES) for the endovascular treatment of cerebral aneurysms. MicroVention's HES coil is a unique embolization device that is designed to combine the features of greater space filling and improved healing of microporous expandable hydrogel with the delivery and handling characteristics of a detachable platinum coil. A cerebral aneurysm is a ballooning of a weakened region of a blood vessel. If left untreated, an aneurysm may continue to weaken until it ruptures and bleeds into the brain. It is estimated that approximately 2 to 5 percent of the U.S. population have cerebral aneurysms, although most go undetected. Each year approximately 150,000 patients worldwide are treated for cerebral aneurysms, with an estimated 25 percent of these patients treated by endovascular coil embolization rather than traditional surgical approaches. Endovascular embolization is one of the fastest growing markets in vascular medical technology.
About MicroVention, Inc.
MicroVention, Inc. (http://www.microvention.com/) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System to treat cerebral aneurysms. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in various other countries.
CONTACT: Michael Kleine, President, CEO, or William Hughes, VicePresident, CFO, both of MicroVention, +1-949-461-3314, or fax,+1-949-461-3329; or Media, Matt Clawson of Allen & Caron, Inc.,+1-949-474-4300, or fax, +1-949-474-4330, for MicroVention